Results 211 to 220 of about 693,447 (358)

Nanobody‐Decorated Lipid Nanoparticles for Enhanced mRNA Delivery to Tumors In Vivo

open access: yesAdvanced Healthcare Materials, EarlyView.
This study presents a targeted mRNA‐LNP platform engineered with anti‐PSMA nanobodies for prostate cancer therapy. Using different in vivo models, the authors demonstrate selective uptake and mRNA delivery in PSMA+ cancer cells. However, while targeting is enhanced, mRNA delivery efficacy is limited by tissue penetration, tumor necrosis, and immune ...
Pol Escudé Martinez de Castilla   +16 more
wiley   +1 more source

Peptide Display Directed Assembly of Biopolymer Core–Silica Shell Particles

open access: yesAdvanced Healthcare Materials, EarlyView.
Bacterial cells are engineered to produce biopolyester particles displaying peptides mediating growth of silica. Peptide‐coated biopolyester particles are treated with silica precursors and silica shell formation is studied. Transmission electron microscopy shows silica‐coated BPs which are formed after the silicification treatment. Characterization of
Deeptee Chandrashekhar Pande   +2 more
wiley   +1 more source

Integration of Bioengineered Tools in Assisted Reproductive Technologies

open access: yesAdvanced Healthcare Materials, EarlyView.
A conceptual illustration depicting the collaboration between a medical professional (right) and a scientist (left). Their connection highlights the integration of scientific research and clinical practice. This representation underscores the role of emerging technologies in bridging fundamental research with applied reproductive healthcare.
Aslı Ak   +3 more
wiley   +1 more source

Coagulation Matters: ATIII‐Enriched Biomolecular Corona Enhances the Hemocompatibility of PEG Nanoparticles

open access: yesAdvanced Healthcare Materials, EarlyView.
Engineering of a functional protein corona with a synergistic heparin‐ATIII complex significantly improves hemocompatibility of PEG nanoparticles. Through deliberate engineering of the protein corona, a 4‐fold reduction in coagulation activation (F1 + 2) without inducing adverse thromboinflammatory reactions (CD11b, C5a) is achieved without disrupting ...
Vaidehi Londhe   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy